Janux Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
69
- Stock Symbol
-
JANX
- Share Price
-
$52.03
- (As of Wednesday Closing)
Janux Therapeutics General Information
Description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Contact Information
Website
www.januxrx.comCorporate Office
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla, CA 92037
- United States
Corporate Office
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla, CA 92037
- United States
Janux Therapeutics Timeline
Janux Therapeutics Stock Performance
As of 13-Nov-2024, Janux Therapeutics’s stock price is $52.03. Its current market cap is $2.73B with 52.5M shares.
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$52.03 | $52.84 | $7.79 - $65.60 | $2.73B | 52.5M | 597K | -$1.17 |
Janux Therapeutics Financials Summary
As of 30-Sep-2024, Janux Therapeutics has a trailing 12-month revenue of $13M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,747,360 | 170,386 | 234,034 | 433,723 |
Revenue | 13,049 | 8,083 | 8,612 | 3,637 |
EBITDA | (83,883) | (71,024) | (66,250) | (32,816) |
Net Income | (60,536) | (58,293) | (63,059) | (32,672) |
Total Assets | 695,019 | 380,407 | 364,010 | 379,824 |
Total Debt | 23,431 | 24,542 | 25,305 | 194 |
Janux Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Janux Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Janux Therapeutics Comparisons
Industry
Financing
Details
Janux Therapeutics Competitors (65)
One of Janux Therapeutics’s 65 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
Lava Therapeutics | Formerly VC-backed | Utrecht, Netherlands |
Janux Therapeutics Patents
Janux Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230357429-A1 | Optimized antibodies targeting trop2 and uses thereof | Pending | 04-May-2022 | ||
US-20230357447-A1 | Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof | Pending | 04-May-2022 | ||
US-20240059790-A1 | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens | Pending | 04-Apr-2022 | ||
AU-2023250347-A1 | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens | Pending | 04-Apr-2022 | ||
AU-2022272906-A9 | Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens | Pending | 12-May-2021 | A61K47/6849 |
Janux Therapeutics Signals
Janux Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Janux Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
28.75 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,035
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Janux Therapeutics FAQs
-
When was Janux Therapeutics founded?
Janux Therapeutics was founded in 2017.
-
Where is Janux Therapeutics headquartered?
Janux Therapeutics is headquartered in La Jolla, CA.
-
What is the size of Janux Therapeutics?
Janux Therapeutics has 69 total employees.
-
What industry is Janux Therapeutics in?
Janux Therapeutics’s primary industry is Drug Discovery.
-
Is Janux Therapeutics a private or public company?
Janux Therapeutics is a Public company.
-
What is Janux Therapeutics’s stock symbol?
The ticker symbol for Janux Therapeutics is JANX.
-
What is the current stock price of Janux Therapeutics?
As of 13-Nov-2024 the stock price of Janux Therapeutics is $52.03.
-
What is the current market cap of Janux Therapeutics?
The current market capitalization of Janux Therapeutics is $2.73B.
-
What is Janux Therapeutics’s current revenue?
The trailing twelve month revenue for Janux Therapeutics is $13M.
-
Who are Janux Therapeutics’s competitors?
Ayala Pharmaceuticals, CytomX Therapeutics, Kite Pharma, Inovio Pharmaceuticals, and Lava Therapeutics are some of the 65 competitors of Janux Therapeutics.
-
What is Janux Therapeutics’s annual earnings per share (EPS)?
Janux Therapeutics’s EPS for 12 months was -$1.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »